ProLogium Technology Co., Ltd.: ProLogium Begins Mass Production of High-Energy-Density All-Solid-State Battery, Reaching 381 Wh/kg and 903 Wh/L

ProLogium Technology has begun mass production of its Gen 3.5 Lithium Ceramic Battery (LCB) at its Taiwan facility. The battery achieved 381 Wh/kg and 903 Wh/L energy densities, validated by TÜV and UL Solutions. The company has a decade of commercial production experience and plans to expand globally, targeting automotive, AI data centers, and aerospace markets.

Original reporting
Published Sep 2, 2026, 7:30 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 2, 2026, 8:21 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
ProLogium Technology Co., Ltd.: ProLogium Begins Mass Production of High-Energy-Density All-Solid-State Battery, Reaching 381 Wh/kg and 903 Wh/L — source image
Decision brief

The 30-second read

Low
01

Why it matters

The announcement signals a milestone for solid‑state battery commercialization, potentially affecting battery‑related equities and EV supply chains.

02

Market read

First‑time mass‑production claim could spur interest in battery technology stocks and EV component suppliers.

03

What to watch

Potential regulatory approvals, supply‑chain constraints for ceramic materials, and competition from other solid‑state developers.

Relevance 5/10Novelty 7/10Timing: today

Background

ProLogium announced its Gen 3.5 lithium ceramic battery is now in mass production, achieving 381 Wh/kg and 903 Wh/L, and outlined plans for Gen 4 and global expansion.

Market effects

Highlights progress in solid‑state battery tech, may boost related battery and EV component stocks.

Shows Taiwan's growing role in advanced battery manufacturing, could attract regional supply‑chain interest.

Advances in high‑energy solid‑state cells could influence global EV and data‑center battery demand.

Counterpoint

Without a proven commercial track record at scale, the technology may face cost or reliability hurdles.

Key entities

  • ProLogium Technology Co., Ltd.

    Taiwanese solid‑state battery manufacturer.

Related articles

Low

ProLogium Technology Co., Ltd.: Mercedes-Benz and ProLogium have entered into a joint testing agreement, including a preliminary technology evaluation of ProLogium's latest Gen4 Superfluidized All Inorganic Solid State Battery Cell Technology

Mercedes-Benz and ProLogium have signed a joint testing agreement for ProLogium's Gen4 solid-state battery cells, building on a decade-long partnership. The agreement grants Mercedes-Benz priority access to test the technology, which offers high energy density, safety, and performance. ProLogium plans to go public on NASDAQ in 4Q2026 under the ticker PRLG.

$PRLGMed

ProLogium Ships First Solid-State Cells as Dunkirk Factory Rises

ProLogium Technology has started mass production of its lithium-ceramic battery cells in Taiwan, achieving 381 watt-hours per kilogram. The company is building a €5.2 billion gigafactory in Dunkirk, France, with production expected to begin in 2028. ProLogium aims to list shares on Nasdaq under ticker PRLG via a SPAC merger valued at $3.8 billion. The company has partnerships with Mercedes-Benz and Rimac, and its technology promises higher energy density and improved safety for electric vehicles

$TDACMedAI 8/10

ProLogium Technology Co., Ltd.: ProLogium and Translational Development Acquisition Corp. Announce $50 Million Committed Primary Capital Investment to Support Proposed Business Combination

ProLogium and Nasdaq-listed SPAC TDAC said they secured commitments for a $50 million primary capital investment from existing ProLogium shareholders at a pre-money valuation of about $3.8 billion to support their proposed business combination. Proceeds are earmarked for scaling next-generation lithium ceramic batteries and building a Dunkirk, France gigafactory, alongside a French subsidy package up to €1.375 billion.

$LLYMed

Retatrutide Cut Sleep Apnea Breathing Events Up to 60.6% in Lilly Trial, but the Weekly Shot Remains Unapproved

Eli Lilly reported that retatrutide, an experimental weekly injection, reduced breathing interruptions in sleep apnea patients by up to 60.6% in an 80-week trial. The drug also showed a 48.1% reduction in a separate trial involving Type 2 diabetes patients. Lilly plans to seek FDA approval in early 2027, but the drug is not yet approved for any use. The results were presented at ObesityWeek 2026, with full peer-reviewed data not yet published.

$LHXMed

Airlines cancel thousands more flights after FAA ground stop

A router installed by L3Harris caused a nationwide US flight shutdown on November 13, leading to 4,500 cancellations and 4,400 delays on November 14. Transportation Secretary Sean Duffy noted the disruption was not a cyberattack but due to potential user or installer error. Major airlines canceled about 20% of flights, with JetBlue canceling 40%. The FAA is investigating and expects operations to normalize by late November 15. Duffy requested $50 billion to upgrade air traffic control systems.